Feb 22, 2022
Cardiac amyloidosis is an often overlooked and thus misdiagnosed form of a restrictive cardiomyopathy in which delayed diagnosis is associated with significant morbidity and mortality. Immunoglobulin light chain (AL) cardiac amyloidosis is the most deadly from of cardiac amyloidosis but significant progress has been...
Feb 15, 2022
It is important that patients with reduced heart function are treated with drugs that have been documented to prolong survival. In this interview, Finn Gustafsson, MD, PhD and Michelle Kittleson MD, FACC, along with Michael Mikolaj MD, MPH, FACC, discuss What Should Optimal Medical Therapy Look Like Prior to Intervention?
Feb 8, 2022
After a heart attack, levels of blood lipids such as low-density lipoprotein cholesterol (LDL-C) may influence the risk of further cardiovascular events. In this analysis, we determined that even when LDL-C levels are controlled with a statin, elevated levels of another blood lipid called lipoprotein(a) are associated...
Feb 1, 2022
Is atrial fibrillation ablation a "slam dunk" for athletes? When would a clinician favor pharmacotherapy?
In this episode, Michael S. Emery, MD, MS, FACC debates Mark S Link, MD on Atrial Fibrillation Management in Athletes, moderated by Alison L. Bailey, MD FACC.